NCT07523555 2026-04-13
ADAPT-HEM
Beijing Biotech
Phase 1/2 Recruiting
Clinical Trials
14 trialsNCT07471789 2026-03-13
Safety and Efficacy of GYA01 (CART84) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia (AML) and Acute Lymphoblastic T Leukemia Patients (T-ALL).
Gyala Therapeutics
Phase 1/2 Recruiting
NCT06316856 2026-03-10
CD5 Chimeric Antigen Receptor (CAR) T Cells in Subjects With Relapsed or Refractory T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2 Recruiting
NCT06064903 2025-12-02
CD7-CAR01
Bambino Gesù Hospital and Research Institute
Phase 1/2 Recruiting
NCT06316427 2025-11-26
Autologous and Donor-derived CD7 CAR-T Therapy in Refractory or Relapsed T-cell Malignancies
Beijing GoBroad Hospital
Phase 1/2 Recruiting
NCT07070323 2025-11-26
nanobody CD5
Beijing GoBroad Hospital
Phase 1/2 Recruiting
NCT07075328 2025-11-21
A Phase I/II Study of OJP-001 in Patients With Adult T-cell Leukemia/Lymphoma
Otsuka Medical Devices Co., Ltd. Japan
Phase 1/2 Recruiting
NCT05658640 2025-09-16
HEM-iSMART D
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05745714 2025-09-16
HEM-iSMART C
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT05751044 2025-09-16
HEM-iSMART B
Princess Maxima Center for Pediatric Oncology
Phase 1/2 Recruiting
NCT04315324 2025-08-15
Study to Test OBI-3424 in Patients With T-Cell Acute Lymphoblastic Leukemia (T-ALL) or T-Cell Lymphoblastic Lymphoma (T-LBL)
SWOG Cancer Research Network
Phase 1/2 Recruiting
NCT06874946 2025-03-13
Phase I/II
Peking University People's Hospital
Phase 1/2 Recruiting
NCT06420076 2024-11-12
BAH246
Essen Biotech
Phase 1/2 Recruiting
NCT06376721 2024-04-19
Linperlisib Combined With Camrelizumab and Pegaspargase in Advanced or Relapsed/Refractory NK/T-cell Lymphoma
Beijing Tongren Hospital
Phase 1/2 Recruiting